| Bioactivity | Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I)[1]. |
| Invitro | "氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[2]。氘代化合物的潜在优势：（1）延长体内半衰期。氘代化合物或能够延长化合物的药代动力学特征，即延长体内半衰期。由此可提高化合物安全性、有效性和耐受性，并增加给药的便捷性。（2）提高口服生物利用度。氘代化合物或能够减少肠壁和肝脏中不需要的代谢 (首过代谢) 程度，使得更大比例的未代谢药物到达作用的目标位置。生物利用度高决定其在低剂量下具有活性以及更好的耐受性。（3）改善代谢特征。氘代化合物或能够减少有毒或反应性代谢物的形成，改善药物代谢状况。（4）改进药品安全性。氘代化合物或能够减少或消除药物化合物的不良副作用，具有安全性。（5）保留治疗特性。氘代化合物有望保留和此前研究中氢类似物相似的生化效力和选择性。" |
| Name | Deuruxolitinib-d8 |
| CAS | 1513883-39-0 |
| Formula | C17H10D8N6 |
| Molar Mass | 314.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Amanda T. WAGNER, et al. Treatment of hair loss disorders with deuterated jak inhibitors. Patent WO2017192905A1 [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. |
Deuruxolitinib-d8
CAS: 1513883-39-0 F: C17H10D8N6 W: 314.41
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.